The purpose of this study was to develop film-forming emulsions (FFE) facilitating long-term treatment of chronic pruritus with capsaicinoids. To this end, oil-in-water emulsions, which comprise dispersions of sustained-release polymers, were examined. Such emulsions form a film when applied to the skin and encapsulate the oily drug solution in a dry polymeric matrix. Permeation of the antipruritic drug nonivamide (NVA) is controlled by the matrix. Permeation rates of NVA from FFE and its concentration in the skin are equivalent to those achieved with a conventional semisolid formulation, but can be maintained for a longer period of time. FFE may therefore improve the treatment of chronic pruritus with capsaicinoids by enhancing patient compliance by means of a sustained-release regimen.

1.
Ständer S, Schäfer I, Phan NQ, Blome C, Herberger K, Heigel H, Augustin M: Prevalence of chronic pruritus in Germany: results of a cross-sectional study in a sample working population of 11,730. Dermatology 2010;221:229-235.
2.
Ständer S, Luger T, Metze D: Treatment of prurigo nodularis with topical capsaicin. J Am Acad Dermatol 2001;44:471-478.
3.
Proksch E: The role of emollients in the management of diseases with chronic dry skin. Skin Pharmacol Physiol 2008;21:75-80.
4.
Paice JA, Ferrans CE, Lashley FR, Shott S, Vizgirda V, Pitrak D: Topical capsaicin in the management of HIV-associated peripheral neuropathy. J Pain Symptom Manage 2000;19:45-52.
5.
Anand P, Bley K: Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth 2011;107:490-502.
6.
Ikoma A: Neuroanatmy of itch; in Misery L, Ständer S (eds): Pruritus. New York, Springer, 2010, pp 3-6.
7.
Serra J, Campero M, Ochoa J: Flare and hyperalgesia after intradermal capsaicin injection in human skin. J Neurophysiol 1998;80:2801-2810.
8.
Ständer S, Luger TA: Neuroreceptors and neuromediators; in Misery L, Ständer S (eds): Pruritus. New York, Springer, 2010, pp 7-16.
9.
Lunter DJ, Daniels R: New film forming emulsions containing Eudragit® NE and/or RS 30D for sustained dermal delivery of nonivamide. Eur J Pharm Biopharm 2012;82:291-298.
10.
Hydrophile Capsaicinoid Creme 0.025%/0.05%/0.1% (NRF 11.125); in: Neues Rezeptur Formularium. Eschborn, Govi, 2010.
11.
Reyes-Escogido Mde L, Gonzalez-Mondragon EG, Vazquez-Tzompantzi E: Chemical and pharmacological aspects of capsaicin. Molecules 2011;16:1253-1270.
12.
Simon GA, Maibach HI: The pig as an experimental animal model of percutaneous permeation in man: qualitative and quantitative observations - an overview. Skin Pharmacol Appl Skin Physiol 2000;13:229-234.
13.
Monteiro-Riviere NA, Baynes RE, Riviere JE: Animal skin morphology and dermal absorption; in Roberts MS, Walters KA (eds): Dermal Absorption and Toxicity Assessment. New York, Informa Healthcare, 2008, pp 17-36.
14.
Lehmann K, Dreher D: Mischbarkeit wässriger Poly(meth)acrylat-Dispersionen für Arzneimittelüberzüge. Pharm Ind 1986;48:1182-1183.
15.
Hadgraft J: Skin, the final frontier. Int J Pharm 2001;224:1-18.
16.
Higuchi T: Rate of release of medicaments from ointment bases containing drugs in suspension. J Pharm Sci 1961;50:874-875.
17.
Higuchi WI: Analysis of data on the medicament release from ointments. J Pharm Sci 1962;51:802-804.
18.
Franz TJ, Lehman PA, Franz SF, North-Root H, Demetrulias JL, Kelling CK, Moloney SJ, Gettings SD: Percutaneous penetration of N-nitrosodiethanolamine through human skin (in vitro): comparison of finite and infinite dose applications from cosmetic vehicles. Fundam Appl Toxicol 1993;21:213-221.
19.
Franz TJ, Lehman PA, Raney SG: Use of excised human skin to assess the bioequivalence of topical products. Skin Pharmacol Physiol 2009;22:276-286.
20.
Klang V, Haberfeld S, Hartl A, Valenta C: Effect of γ-cyclodextrin on the in vitro skin permeation of a steroidal drug from nanoemulsions: impact of experimental setup. Int J Pharm 2012;423:535-542.
21.
Lehman PA, Raney SG, Franz TJ: Percutaneous absorption in man: in vitro-in vivo correlation. Skin Pharmacol Physiol 2011;24:224-230.
22.
Kasting GB: Kinetics of finite dose absorption through skin 1. Vanillylnonanamide. J Pharm Sci 2001;90:202-212.
23.
Schlupp P, Blaschke T, Kramer KD, Höltje H-D, Mehnert W, Schäfer-Korting M: Drug release and skin penetration from solid lipid nanoparticles and a base cream: a systematic approach from a comparison of three glucocorticoids. Skin Pharmacol Physiol 2010;24:199-209.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.